Latigo Biotherapeutics (NASDAQ:LTGO) Reaches New 1-Year High – Should You Buy?

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO)’s stock price reached a new 52-week high on Friday . The stock traded as high as $22.90 and last traded at $22.39, with a volume of 143831 shares. The stock had previously closed at $21.40.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Latigo Biotherapeutics to a “hold” rating in a report on Saturday, August 15th.

Latigo Biotherapeutics Stock Up 4.5%

Insider Transactions at Latigo Biotherapeutics

In related news, major shareholder Foresite Capital Management V, bought 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the acquisition, the insider directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. The trade was a 7.49% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James B. Tananbaum bought 140,000 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were purchased at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the transaction, the director directly owned 2,008,024 shares in the company, valued at approximately $36,144,432. This trade represents a 7.49% increase in their position. The disclosure for this purchase is available in the SEC filing.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.